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Background and Aim. Numerous reports have indicated that dealing with stressors in life is a main risk factor for the occurrence
and progression of cognitive and memory impairment. Available treatments such as benzodiazepine and antidepressants address
only certain aspects of this stress disorder and have numerous side effects. %e present study was aimed at investigating the effect
of diosmetin, as a flavonoid compound with potent antioxidant and anti-inflammatory effects, on cognitive impairment and
chronic stress memory. Materials and Methods. In the present experimental study, male NMRI mice were exposed to chronic
unpredictable mild stress (CUMS) paradigm for 35 days. Diosmetin (at doses of 10, 20, and 40mg/kg. i.p.) or diosmetin solvent
(normal saline +DMSO, 1ml/kg; i.p.) was administered 30min before stress induction. After 28 days, memory and cognitive
performance were assessed by shuttle box and novel object recognition tests. Finally, antioxidant capacity (FRAP) and
malondialdehyde (MDA) level of serum and brain, and serum corticosterone level were evaluated. Results. Behavioral tests showed
that CUMS significantly reduced the secondary latency in passive avoidance memory test and diagnosis index in novel object
recognition test compared to the control group (P< 0.001), whereas treatment with diosmetin (20 and 40mg/kg) significantly
improved memory performance in the two tests (P< 0.001). In addition, diosmetin (40mg/kg) could pronouncedly suppress
increase in serum corticosterone levels, reduction in antioxidant capacity, and production of excess MDA caused by CUMS
compared to the control group (P< 0.01, P< 0.001, and P< 0.001, respectively). Conclusion. Chronic stress can impair memory
and cognition and treatment with diosmetin can partly improve this disorder in male mice by increasing the antioxidant capacity
of brain tissue and serum and improving serum corticosterone levels.
1. Introduction
Memory is a process by which acquired information is stored
and re-read through learning. Learning is the process of ac-
quiring new information from the surrounding world while
memory refers to the ability to memorize and retrieve it [1]. In
the cerebral cortex, there are primary and secondary motor
areas, primary and secondary sensory areas, and special areas
for visual, auditory, and physical sensations. In addition, there
are other cortical areas in the cortex called communication
areas, which receive and analyze signals from multiple areas of
the motor and sensory cortex, and subcutaneous structures.
Synapses that are subjected to repetitive presynaptic nerve
stimulation cause changes in the excitability of postsynaptic
neurons. %ese changes include the facilitation of neuron
activation, changes in the pattern of neurotransmitter release,
and secondary messenger formation, which eventually lead to
learning [2]. Synaptic facilitation, long-term potentiation
(LTP), and long-term depression (LTD) are the most im-
portant mechanisms involved in memory formation [2].
Studies have shown that chronic stress can block
chemical reactions in the brain that are useful for learning
and memory. Chronic stress can also impair growth,
learning, and memory [3]. Chronic stress induces its effect
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by activating the hypothalamic-pituitary-adrenal (HPA) axis
and increasing glucocorticoid levels. Glucocorticoids can
have short- and long-term effects on cognitive behavior and
processes through genomic and nongenomic mechanisms.
Evidence suggests that long-term exposure to stress or
glucocorticoids causes numerous changes in the structure of
the hippocampus, including neurochemical alteration,
changes in irritability, neurogenesis, neuronal morphology,
and even cell death. Such changes in the hippocampus have
been proposed as the underlying mechanism of stress-in-
duced cognitive impairments [4].
Treatments may include anxiolytics such as benzodiaze-
pines (lorazepam, diazepam), acetylcholinesterase inhibitors
(rivastigmine or donepezil) that are also used for the treat-
ment of Alzheimer’s disease, or antidepressants (fluoxetine,
imipramine, etc.). %ese treatments address some aspects of
the disorder that do not necessarily lead to appropriate re-
sponses and have numerous side effects. In seeking out new
therapeutic products for the treatment of neurodegenerative
disorders with fewer side effects, research across the world has
consistently shown the efficacy of different types of herbal
remedies in various animal models [5–7].
Diosmetin (5, 7, 3′, -trihydroxy-4′,-methoxyflavone,
Figure 1(a)) is a methylated flavone which is naturally found
in the citrus family and in plants of the genus Lamiaceae,
Teucrium, Portuguese, and olive leaves [8, 9]. Pharmaco-
logically, diosmetin has been reported to exhibit anti-cancer,
antimicrobial, antioxidant, and anti-inflammatory, phy-
toestrogenic, and osteogenic activity [8, 9]. Diosmetin also
acts as an antioxidant receptor agonist for tropomyosin
receptor kinase B (TrkB) [10]. Diosmetin exhibits neuro-
protective effects and increases serum antioxidant capacity
in vitro due to its chemical structure that is similar to that of
catechin and quercetin flavonoids, and by converting it to
the intermediate compound luteolin [11, 12].
Antioxidant effects of diosmetin have been reported
to be induced by inhibition of nitric oxide (NO) pro-
duction and by increasing the serum antioxidant capacity
of animals given this compound [13]. Diosmetin also
enhances antioxidant activity in monocytes by inhibiting
the production of intracellular reactive oxygen species
[14] and malondialdehyde (MDA), and enhancing the
intracellular antioxidant effects of superoxide dismutase
(SOD) and catalase and glutathione peroxidase (GPx)
[15]. %is compound produces its protective effects by
reducing oxidative stress markers and preventing oxi-
dative damage to the retinal DNA on apoptosis of
adriamycin-induced retinal granule epithelial cells [16].
%e anti-inflammatory properties of diosmetin have been
demonstrated through reduced nitric oxide production
and decreased secretion of tumor necrosis factor-alpha
(TNF-α) from microglia and macrophages in vitro [15].
Diosmetin can suppress the apoptosis of T48 cells by
activating the phosphorylation of AKt and ERK protein
kinases [17].
Given the negative effects of chronic stress on cognition
and memory and the numerous protective effects of dio-
smetin, this study investigated the effect of diosmetin on
cognitive impairment and memory due to chronic stress.
2. Materials and Methods
2.1.Animals. A total of 80 adult NMRImice were selected in
the weight range of 20–30 g and kept in appropriate con-
ditions (21± 2)°C, 12-hour light and 12-hour dark with free
access to water and food.
All procedures of this study were conducted according to
the regulations of the University and the Guide for the Care
and Use of Laboratory Animals of National Institutes of
Health (ethics number: IR.SKUMS.REC.1395.157) and
Guide for the Care and Use of Laboratory Animals (Eighth
Edition, 2011, published by the National Press).
2.2.ChronicUnpredictableMild Stress (CUMS)Procedureand
Experimental Design. CUMS was induced by a method
described by Willner with minor modification [18]. %e
paradigm included separate stressors, which were randomly
set up. All stressors are listed in Table 1. Animals were
divided into CUMS and normal groups. In CUMS groups,
animals were exposed to stressors for 2 weeks and then
distributed into 4 groups (n� 10 per group) and received
solvent (saline + 2% DMSO) and/or diosmetin (Sigma
Aldrich, United Kingdom, D7321) (10, 20, 40mg/kg) for 3
weeks while being exposed to CUMS. Besides, normal an-
imals were divided into 4 groups and received normal saline
or diosmetin (10, 20, 40mg/kg) for 3 weeks (Figure 1(b)).
It should be noted that the injections of the drugs were
conducted intraperitoneally and the drugs dosages were
selected based on previous studies [19].
After completion of the behavioral test, the animals were
anesthetized with ketamine and xylazine (60 and 10mg/kg,
respectively) and blood samples and the hippocampus tis-
sues were isolated and immediately transferred to the freezer
set at −70°C.
2.3. Cognitive Function and Memory Test through Novel
Object. %e novel object recognition test is a method to test
the cognitive function and memory of the animal. %e test
was done according to the method of Bertaina et al. In
summary, a black wooden box of 40× 40× 40 cm was used.
Animals were placed in the apparatus on the day before the
test to adapt to it. After 24 hours, two identical objects were
placed in two corners of the box, allowing the animal to
identify and examine the objects for 5min. %e animal was
then removed from the box and 30minutes later, the test was
performed in which one of the objects changed and the
length of time the animal spent identifying each object was
recorded [20]. %is method consists of three stages of ha-
bituation, learning (T1), and memory testing (T2). In this
method, the difference between the time the animal spends
identifying an old object (T1) and a new object (T2) is used
as the criterion to evaluate memory, known as the recog-
nition index or discrimination index.
Recognition index�T2/(T1+T2).
2.4. Passive Avoidance Memory Test through Shuttle Box.
%e shuttle box includes an electric shocker and two light
and dark chambers separated by a guillotine door. %e
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bottom of the apparatus is made of a conductive metal grid.
In the first and second days of the test, the animal is allowed
to adapt to the apparatus by allowing it to move freely
between the light and dark chambers for 5 minutes. On the
third day, when the mouse was released into the bright
room, 20 seconds later the guillotine door was removed and
the time of entry into the dark room was recorded by a
stopwatch. When the animal entered the dark chamber, the
animal was given an electric shock (1mA, 1 sec, 1 time) and
then the animal was ejected. On the fourth day, the time
interval between being in the bright room and entering the
dark room was measured and expressed as the delay time (to
a maximum of 60 sec) [21].
2.5. Serum Corticosterone Determination. Serum cortico-
sterone levels were measured by specific mouse cortico-
sterone ELISA kit (Abcam, United Kingdom, ab108821). All
reagents and samples were prepared according to the kit
instruction. %e absorbance of samples was assayed on
microplate ELISA reader at a wavelength of 450 nm. Results
were reported in ng/ml [22].
2.6. Antioxidant Capacity Determination. %e total antiox-
idant capacity of serum and brain tissue was assessed by the
FRAP method described by Benzie, based on the ability of
serum and tissue sample to recover ferric ions to ferrous ions
in the presence of 2,4,6-tripyridyl-s-triazine (TPTZ), and the
absorbance was recorded by a spectrophotometer. Briefly,
50 μl of 10% homogenate suspension extract or serum was
added to 1.5ml of freshly prepared reactant (including
acetate buffer solution with pH 3.6, TPTZ, HCl 20mM, and
FeCl3 20mM) and incubated at 37°C for 10min [23]. %e
intensity of blue color formed by the complex between
ferrous ion and TPTZwas measured by a spectrophotometer
at 593 nm. All data were reported in μM [21, 24].
2.7. MDA Level Determination. %e MDA levels of hippo-
campus and serum were measured according to the method
described by Zarrindast et al. (1991). Briefly, 1 g of ho-
mogenized hippocampus (using 2.5% potassium chloride)
sample or 1ml of serum one was added to reaction solution
containing 1ml of 5% trichloroacetic acid and 1ml of 67%
thiobarbituric acid and then centrifuged at 2000 g for
15min. %e supernatant was then transferred to another
tube and placed in a boiling bath for 10min. After cooling
down, the absorbance of the prepared sample was measured
by a spectrophotometer at 535 nm, and the results were
expressed as μg/ml [25].
3. Data Analysis
Statistical analysis was performed using SPSS 16 software.
First, data were analyzed using Kolmogorov–Smirnov test
and then homogeneity of variance was estimated using
Levene’s test. One-way ANOVA was used to determine the
significant differences between treatments and Tukey’s post
hoc test was used to compare the mean values. Data were
recorded as mean± standard error and P< 0.05 was con-
sidered as the significance level.
4. Results
4.1. Diosmetin Increased the Secondary Latency of Passive
Avoidance Memory. According to the data regarding the
shuttle box test (Supplementary Table S1 and Figure 2), the
rate of secondary delay in the CUMS group was significantly
reduced compared to the healthy group (P< 0.05). Different
doses of diosmetin in a dose-dependent manner increased the
secondary latency in CUMS animals compared to the solvent-
receiving stress group. However, significant differences were
observed only in the groups receiving doses of 20 and 40mg/
kg (P< 0.05 and P< 0.01, respectively). In the stress-free
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Figure 1: %e molecular structure of diosmetin (A). A schematic paradigm of CUMS procedure and drug treatment (B).
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time increased, but the increase in the secondary delay time
was not significant compared to the solvent-receiving group.
4.2. Diosmetin Improved Memory Parameters in the Novel
Object Test. %e results (Figures 3(a)–3(d), and Supple-
mentary Table S2) revealed that the duration of new object
recognition test decreased significantly in the CUMS group
compared to the healthy group (P< 0.05). Diosmetin in-
creased T2 dose-dependently in the animals under chronic
stress compared to the solvent-treated CUMS group, with
the highest effect at 40mg/kg (P< 0.001, Figure 3(a)).
Under stress-free conditions (Figure 3(b)), the duration
of new object recognition dose-dependently increased. In
the groups given diosmetin at doses of 20 and 40mg/kg, new
object recognition time significantly increased in compari-
son to the solvent-receiving group (P< 0.05).
According to the results (Figure 3(c)), the recognition
index in the CUMS group showed a significant decrease
compared to the normal group (P< 0.001). In the diosmetin-
treated CUMS groups, the recognition index increased by
more than 50% and was proportional to the increase in
diosmetin dose, and a significant difference was observed in
the chronic stress group receiving solvent (P< 0.001).
In nonstress conditions (Figure 3(d)), the results
revealed a significant difference in the recognition index
only in the group receiving 40mg/kg diosmetin compared to
the solvent-receiving group (P< 0.001).
4.3. Diosmetin Reduced Serum Corticosterone Levels.
Corticosterone levels in the CUMS group showed a sig-
nificant increase compared to the healthy group (P< 0.01,
Figure 4(a)). Moreover, serum corticosterone levels de-
creased in the diosmetin-treated chronic stress groups.
However, there was a significant difference in corticosterone
levels between the group given 40mg/kg of diosmetin and
the solvent-receiving group under chronic unpredictable
mild stress (P< 0.01). Corticosterone levels in stress-free
condition (Figure 4(b)) decreased following injection of
different doses of diosmetin in a dose-dependent manner,
but the difference between the solvent group and the dio-
smetin group was not significant. Detailed data regarding the
serum corticosterone levels of different groups are presented
in Supplementary Table S3.
4.4. Diosmetin Reduced the Antioxidant Capacity of Brain
Tissue and Serum. %e antioxidant capacity of brain tissue
showed a significant decrease in the CUMS group compared to
the healthy group (P< 0.001, Figure 5(a)). %e results also
showed that different doses of diosmetin, in a dose-dependent
manner, significantly maintained the antioxidant capacity of
brain tissue in the animals under CUMS compared to the
solvent receiving group (P< 0.001).
In nonstress conditions (Figure 5(b)), the antioxidant
capacity of brain tissue following injection of different doses
of diosmetin showed a dose-dependent increase, with a
significant difference only at 40mg/kg compared to the
solvent-receiving group (P< 0.001).
%e results of serum antioxidant capacity (Figure 5(c))
showed a significant decrease in the CUMS group compared
to the healthy group (P< 0.001). On the other hand, doses of
10, 20, and 40mg/kg diosmetin significantly preserved se-
rum antioxidant capacity in the chronic stress groups
compared to the solvent-receiving group (P< 0.001 and
P< 0.05, respectively).
In nonstress conditions (Figure 5(d)), the antioxidant
capacity of the serum showed a dose-dependent increase
after administration of different doses of diosmetin to the
animals. Significant difference was observed only in the
group that received diosmetin at the dose of 40mg/kg
compared to the solvent-receiving group (P< 0.001). %e
total antioxidant capacity datasets associated with the serum
and hippocampal tissue of all groups are shown in Sup-
plementary Table S4.
4.5. Diosmetin Reduced MDA Level in Hippocampal Tissue
and Serum. As illustrated in Figure 6(a) and 6(c), the MDA
levels of hippocampal tissue and serum significantly
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Figure 2: %e secondary latency (T2) on passive avoidance memory in shuttle box test in CUMS conditions (A) and in nonstressful
conditions (B). Normal: healthy group. Veh: diosmetin solvent received group. Dios: diosmetin-receiving group (10, 20, 40mg/kg).
$P< 0.05 compared to the normal group. ∗P< 0.05 and ∗∗P< 0.01 compared to the vehicle treated group.
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Figure 3: %e duration of new object recognition (T2) in CUMS condition (A) and in stress-free condition (B). %e recognition index in
CUMS condition (C) and in stress-free condition (D) in the novel object test. Normal: healthy group. Veh: diosmetin solvent-receiving
group. Dios: diosmetin-receiving group (10, 20, 40mg/kg). $P< 0.05 and $$$P< 0.001 compared to the normal group. ∗P< 0.05, ∗∗P< 0.01,
and ∗∗∗P< 0.001 compared to the vehicle-treated group.
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Figure 4: Serum corticosterone levels in CUMS condition (A) and stress-free conditions (B). Normal: healthy group. Veh: diosmetin
solvent-receiving group. Dios: diosmetin-receiving group (10, 20, 40mg/kg). $$P< 0.01 compared to the normal group. ∗∗P< 0.01
compared to the vehicle-treated group.
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increased in the CUMS group compared to the normal
group (P< 0.001). Additionally, our results revealed a dose-
dependent and significant reduction in both serum and
hippocampal tissue MDA levels in diosmetin-treated CUMS
groups when compared to solvent-treated CUMS group
(P< 0.001).
Effects of different doses of diosmetin on MDA con-
centration in normal animals are illustrated in Figure 6(b)
and 6(d). Our results indicated that diosmetin at 40mg/kg
significantly reduced MDA level in hippocampal tissue
compared to the solvent-treated normal group (Figure 6(b),
P< 0.05). Additionally, no significant difference was ob-
served in serum MDA levels between diosmetin-treated
normal groups and solvent-treated normal group
(Figure 6(d)). Supplementary Table S5 contains datasets
related to the MDA levels of hippocampal tissue and serum.
5. Discussion
In the present study, the effect of diosmetin on memory
impairment due to CUMS was investigated. %e results
showed that five weeks of CUMS impaired memory func-
tion. %e symptoms were associated with increased
hypothalamic-pituitary-adrenal (HPA) axis activity, de-
creased antioxidant capacity, and increased MDA produc-
tion in the brain hippocampal tissue and serum. Diosmetin
treatment significantly restored CUMS-induced behavioral
changes. Moreover, diosmetin significantly maintained
normal corticosterone levels, increased the antioxidant ca-
pacity, and decreased the MDA levels of hippocampal tissue
and serum in animals under CUMS.
%e results from the novel object recognition and shuttle
box tests were similar to those of previous studies which
showed that chronic stress can notably diminish memory
and cognitive performance [26, 27]. According to the results
from behavioral tests, in chronic passive avoidance memory
(shuttle box), which reflects the animal’s cognitive ability
and recall of obtained information in avoiding the disturbing
stimulus of electric shock, chronic stress impairs electrical
shock avoidance. %is test shows damage to the hippo-
campus and, to some extent, the amygdala. Inhibition of
these two regions by drugs or their degradation may inhibit
chronic stress memory impairment [28]. Furthermore, the
novel object recognition test strongly represents visual
cognitive memory and is considered as a short-termmemory
model [29, 30]. It has been shown that in chronic stress
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Figure 5: Antioxidant capacity of brain tissue in CUMS (A) and under stress-free conditions (B) and serum antioxidant capacity CUMS
conditions (C) and stress-free conditions (D). Normal: healthy group. Veh: diosmetin solvent-receiving group. Dios: diosmetin-receiving
group (10, 20, 40mg/kg). $$$P< 0.001 compared to the normal group. ∗ (P)< 0.05, ∗∗P< 0.01, and ∗∗∗P< 0.001 compared to the vehicle-
treated group.
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model, in addition to the hippocampus, the prefrontal cortex
structure is also likely to be affected [14].
Diosmetin increased the speed of learning in chronic
stress animals in the avoidance memory test and also sig-
nificantly increased the time of avoiding electric shock and
entering the dark room compared to the group under stress.
Similarly, different doses of diosmetin significantly increased
the recognition index in novel object recognition test by
more than 50% in comparison with the group under stress.
In the other studies, various flavonoid compounds such as
diosmin (a flavone glycoside of diosmetin) [31], quercetin
[32, 33], hesperetin [34], luteolin [35, 36], crocin [37], and
nobiletin [38] h have been found to improve memory and
learning performance in animals.
One of the important mechanisms involved in cognitive
and memory impairment is the effect of chronic stress
through elevation of glucocorticoid levels and activation of
the HPA axis. In fact, it seems that chronic stress constantly
stimulates the HPA axis, leading to glucocorticoids release.
As a result, brain regions related to memory formation and
consolidation, such as hippocampus and amygdala, undergo
a variety of changes due to persistent exposure to
glucocorticoids [4]. %e corticosterone, as the main gluco-
corticoid in rodents, attenuates synaptic plasticity in the hip-
pocampus, prefrontal cortex, and striatum, that accompany
behavioral and cognitive impairment [39–42]. In the present
study, it was found that the level of corticosterone significantly
increased in the CUMS group in comparison with stress-free
animals, which is consistent with the proven hypothesis
mentioned above. %e use of corticosterone synthesis inhibi-
tors such as metyrapone can improve the stress-related cog-
nitive impairment induced by corticosterone [40, 42].
Additionally, administration of diosmetin to animals under
CUMS maintained a normal corticosterone level, which may
have partly contributed to the reversal of memory deficit in-
duced by chronic stress. Similarly, there have been various
reports on the effect of flavonoid compounds, such as quer-
cetin, luteolin, and crocin, on the reduction of corticosterone
levels in stress conditions [22, 33, 43].
On the other hand, one of the notable results of this study
was the nonsignificant reduction in corticosterone levels in
diosmetin-treated normal groups when compared with saline-
treated normal group. Unfortunately, there was insufficient
data to support the current finding, whereby it is necessary to
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Figure 6: Evaluation of MDA level of hippocampal tissue in CUMS condition (A) and in stress-free condition (B) and serumMDA levels in
CUMS condition (C) and in stress-free condition (D). Normal: healthy group. Veh: diosmetin solvent-receiving group. Dios: diosmetin-
receiving group (10, 20, 40mg/kg). $$$P< 0.001 compared to the normal group. ∗∗∗P< 0.001 compared to the vehicle-treated group.
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investigate the exact mechanism associated with this result
because previous studies indicated that memory performance
deficits correlate to not only very high but also very low levels
of corticosterone [40, 42]. However, thememory performances
of diosmetin-treated stress-free animals were not proportional
to the corresponding reduced corticosterone levels.
Frequent exposure of neural cells to glucocorticoids due
to chronic stress increases ROS and RNS production and the
sensitivity of neurons to the deleterious effects of the latter
compounds, which play a pivotal role in memory impairment
[44]. In addition, oxidative stress and lipid peroxidation can
damagememory through themechanism of oxidative damage
to the hippocampus and pyramidal cell apoptosis that reduces
glucocorticoid receptors and increases glucocorticoid pro-
duction [45]. In the present study, the results regarding
antioxidant capacity and MDA production in chronic stress
conditions were greatly consistent with previous studies.
One of the prominent properties of flavonoid compounds is
their antioxidant effect that has been investigated in numerous
studies on cognitive and memory impairment [22, 33, 46, 47].
%e effect of diosmetin in preventing various cell damage due to
oxidative stress and toxins has been demonstrated in vitro. In
previous studies, diosmetin has been found to protect hepa-
tocytes against cellular damage caused by iron accumulation
and tert-butyl hydroperoxide toxin [10, 48]. Diosmetin has also
exhibited therapeutic and protective effects in experimental
models of various diseases such as retinal damage, oxidative
damage to erythrocyte and serum induced by AAPH and
CuCl2, acute pancreatitis caused by ceruline, and acute lung
injury. %ese effects are produced due to the enzymatic and
nonenzymatic effects of antioxidants (myeloperoxidase deple-
tion, depletion of reactive oxygen species, depletion of anti-
oxidant enzymes, and decrease in lipid peroxidation) and the
reduction of expression of inflammatory factors and oxidative
stress-regulating genes and proinflammatory cytokines (TNF-α,
IL-1β, and IL-6) of this compound [10, 16, 19, 49]. In the
present study, consistent with the results of previous studies,
different doses of diosmetin significantly and dose-dependently
preserved the antioxidant capacity and reduced MDA
production in CUMS animals.
6. Conclusion
Taken together, according to the results of this study,
some of memory-enhancing properties of diosmetin in
CUMS condition might be associated with the efficacious
regulation of oxidative stress through augmentation of
total antioxidant capacity and decreasing of lipid per-
oxidation as well as preserving normal corticosterone.
However, further studies are needed to elucidate the
precise mechanism of how diosmetin affects memory
deficit in chronic stress conditions.
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